Dr Vassiliki Bravis

Sub-specialties: Type 2 Diabetes, Metabolic Disorders, Metabolic Syndrome, Cholesterol Disorders, General Medicine, Endocrinology, Cardiovascular Disease, Abnormal Periods, Hyperlipidaemia, Polycystic Ovary Syndrome, Pituitary Disorders, Adrenal Disorders, Hyperthyroidism, Graves Disease, Hypothyroidism.

Consultations from

£300

Overview

02036532009

Overview

Dr Vassiliki Bravis is an experienced Endocrinologist specialising in Type 2 diabetes, cholesterol disorders, metabolic syndrome and polycystic ovarian syndrome. She currently holds an Imperial Health Charity Innovation award, which is supporting work into empowering people with diabetes to self-manage through accessing and using technology.

About Dr Vassiliki Bravis

Dr Vassiliki Bravis (FRCP, MBBS, MA Hons Cantab, MRes, PGCert) is a Consultant in Endocrinology & Diabetes.

Vassiliki is an Honorary Senior Clinical Lecturer at Imperial College London and a Fellow of the Royal College of Physicians. She is also North West London Regional Lead for the implementations of TEAMeD-5, which aims to improve the outcomes of people with thyroid eye disease. She currently holds an Imperial Health Charity Innovation award, which is supporting work into empowering people with diabetes to self-manage through accessing and using technology.

Dr Bravis coaches colleagues and trainees working in Diabetes & Endocrinology to deliver improved patient care pathways. She was previously awarded the Sir Francis Avery award, the Diabetes Education Study Group Award and the Diabetes UK Education Award, has received multiple ‘Make a Difference’ awards within her Trust and was shortlisted for the BMJ awards 2019 for the improvement work that she led in inpatient diabetes foot multi-disciplinary care.

Vassiliki qualified as a doctor from the universities of Cambridge and Imperial College London in 2003. She was awarded the NIHR Academic Clinical Fellowship in Endocrinology and Diabetes from 2008 to 2011 and carried out her translational research at Imperial College. She completed her postgraduate training at Hammersmith, Charing Cross and St Mary’s Hospitals in 2014.

In 2015, Vassiliki became a full-time NHS Consultant in Endocrinology, Diabetes and Internal Medicine at Imperial College Healthcare NHS Trust. In 2018 she was awarded a level 4 Local CEA award and in 2019 she became Diabetes Head of Specialty.

Consultation fees:

Initial consultation: £300
Follow-up consultation: £220

Areas of Expertise

Dr Bravis performs the following investigations:

Cardiovascular risk reduction
Specialist endocrine testing
Investigation of irregular periods

Some of the conditions Dr Bravis commonly treats are:

Type 2 diabetes, Secondary diabetes, Steroid-induced diabetes
Cholesterol disorders
Hyperlipidaemia
Metabolic syndrome
Diabetic foot disease
Polycystic Ovarian Syndrome (PCOS)
Pituitary disorders, Adrenal gland disorders
Hyperthyroidism
Graves disease
Hypothyroidism

Additional Information

Qualifications

2000 BA Hons – University of Cambridge
2003 MBBS – Imperial College London
2004 MA Hons – University of Cambridge
2007 MRCP
2010 MRes in Translational Medicine – Imperial College London
2012 MRCP Diabetes & Endocrinology
2013 PGCert in University Learning and Teaching – Imperial College London
2014 CCT in Diabetes & Endocrinology
2020 FRCP

Awards

Imperial Health Charity 2019 Innovation Award
Level 4 Local Clinical Excellence Award 2018
ICHT ‘Make a Difference award’ 2018 – Flow Coaching Academy
ICHT ‘Make a Difference award’ 2018 – Diabetes Foot MDT
BMJ Awards 2019 (shortlisted)
Chairman’s Award 2019 commendation – ‘Driving improvement through data’
Sir Francis Avery award 2010
Diabetes Education Study Group Award 2009
Diabetes UK Education Award 2009
Diabetes UK Education Award 2008

Memberships

Fellow of the Royal College of Physicians
Diabetes UK
Diabetic Foot Study Group
Society for Endocrinology
European Society of Endocrinology Young Endocrinologists & Scientists (EYES)
European Group for Graves Orbitopathy (EUGOGO)

Research Highlights

Dr Vassiliki Bravis has published various notable publications in various peer reviewed journals, including:

Association of Other Autoimmune Diseases With Thyroid Eye Disease. Front Endocrinol (Lausanne) 2021 Mar 5;12:644200. doi: 10.3389/fendo.2021.644200. eCollection 2021.
A ‘Real Life’ Service Evaluation Model for Multidisciplinary Thyroid Eye Services. Front Endocrinol (Lausanne) 2021 May 7;12:669871. doi:10.3389/fendo.2021.669871. eCollection 2021.
Trends in type 2 diabetes mellitus disease burden in European Union countries between 1990 and 2019. Sci Rep 2021 Jul 28;11(1):15356. doi: 10.1038/s41598-021-94807-z.
Arterial spectral waveform analysis in the prediction of diabetic foot ulcer healing. Perfusion. 2021 Oct;36(7):751-756. doi: 10.1177/0267659120957849.
Study protocol for a comparative diagnostic accuracy study of bedside tests used to detect arterial disease in diabetes: TEsting for Arterial disease in Diabetes (TrEAD) study. BMJ Open 2020 Feb 5;10(2):e033753. doi: 10.1136/bmjopen-2019-033753.
Diagnostic Accuracy of Point-of-care tests Used to Detect Arterial Disease in Diabetes: TEsting for Arterial disease in Diabetes (TrEAD) Study. Ann Surg 2020 Dec 29. doi: 10.1097/SLA.0000000000004545. Online ahead of print.
Effectiveness of a multicenter training programme to teach point-of-care vascular ultrasound for the detection of peripheral arterial disease in people with diabetes. J Foot Ankle Res 2018 Jul 16;11:41. doi: 10.1186/s13047-018-0283-0. eCollection 2018.
Fatal epidural abscess from diabetic foot disease. Endocrinol Diabetes Metab Case Rep. 2021 Feb 9;2021:20-0129. doi: 10.1530/EDM-20-0129
Comparison of Diabetic Ketoacidosis in Adults During the SARS-CoV-2 Outbreak and Over the Same Time Period for the Preceding 3 Years. Diabetes Care 2021 Feb;44(2):e29-e31. doi: 10.2337/dc20-2062.
Adverse outcomes in COVID-19 and diabetes: a retrospective cohort study from three London teaching hospitals. BMJ Open Diabetes Res Care 2021 Jan;9(1):e001858. doi: 10.1136/bmjdrc-2020-001858.
Individual and diabetes presentation characteristics associated with partial remission status in children and adults evaluated up to 12 months following diagnosis of type 1 diabetes: An ADDRESS-2 (After Diagnosis Diabetes Research Support System-2) study analysis. Diabetes Res Clin Pract. 2019 Sep;155:107789. doi: 10.1016/j.diabres.2019.107789.
Relationship between islet autoantibody status and the clinical characteristics of children and adults with incident type 1 diabetes in a UK cohort. BMJ Open. 2018 Apr 4;8(4):e020904. doi: 10.1136/bmjopen-2017-020904.
Rationale and protocol for the After Diabetes Diagnosis REsearch Support System (ADDRESS): an incident and high risk type 1 diabetes UK cohort study. BMJ Open. 2017 Jul 12;7(7):e013956. doi: 10.1136/bmjopen-2016-013956.
Fasting among pregnant women with diabetes during Ramadan. Int J Clin Pract. 2012 Sep;66(9):910-1; author reply 910. doi: 10.1111/j.1742-1241.2012.02983.x.
Management of people with diabetes wanting to fast during Ramadan. BMJ 2010 Jun 22;340:c3053. doi: 10.1136/bmj.c3053.
Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan. Int J Clin Pract 2010 Jul;64(8):1095-9. doi: 10.1111/j.1742-1241.2010.02347.x.
Ramadan-focused education and awareness in type 2 diabetes. Diabetologia. 2009 Feb;52(2):367-8. doi: 10.1007/s00125-008-1220-8. Epub 2008 Nov 26.
Effect of oral vitamin D and calcium replacement on glycaemic control in South Asian patients with type 2 diabetes. Int J Clin Pract. 2010 Jul;64(8):1084-9. doi: 10.1111/j.1742-1241.2010.02372.x.

Major insurers served

If your insurer is not listed, please contact us to confirm your coverage. Please note this does not guarantee coverage or fee assurance. Patients should confirm with their insurer to ensure coverage, check if the doctor is fee-assured, or verify if their policy includes the doctor in question.